Friday, 16 October 2026European Markets

TGS Stock Over 29% Up In The Last 21 Sessions

Loading stream...

(VIANEWS) - Shares of TGS (Oslo Børs All-share Index_GI: TGS.OL) rose by a staggering 29.32% in 21 sessions from $134.7 to $174.20 at 13:43 EST on Tuesday, following the last session's upward trend. Oslo Børs All-share Index_GI is rising 0.84% to $1,377.27, after successive sessions in a row of losses.

About TGS

TGS ASA provides geoscience data products and services to the oil and gas industry worldwide. The company offers geophysical multi-client data, including seismic data; and geophysical library, such as gravity, magnetic, seep, geothermal, controlled source electromagnetic, and multibeam data. It also provides geological services comprising digital well logs; and interpretation products and data integration solutions. In addition, the company offers imaging services, which include depth and time imaging; marine, land, and ocean bottom cables and nodes; anisotropic imaging; transition zone processing; multi component processing; shear wave; and 4D time-lapse, as well as wide azimuth data processing. Further, it provides data and analytics solutions; and PRIMA, a multifunction exploration software suite. The company was formerly known as TGS-NOPEC Geophysical Company ASA and changed its name to TGS ASA in June 2021. TGS ASA was founded in 1981 and is headquartered in Oslo, Norway.

Earnings Per Share

As for profitability, TGS has a trailing twelve months EPS of $-13.36.

Volume

Today's last reported volume for TGS is 657917 which is 66% above its average volume of 396321.

More news about TGS (TGS.OL).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com